Brooks Laboratories Limited (BROOKS.BO)
INR 132.4
(7.55%)
INR 132.4
(7.55%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 794.86 Million INR | 27.22% |
| 2022 | 624.8 Million INR | -30.65% |
| 2021 | 900.93 Million INR | 16.94% |
| 2020 | 770.4 Million INR | 11.44% |
| 2019 | 691.32 Million INR | 25.63% |
| 2018 | 550.3 Million INR | -1.22% |
| 2017 | 557.11 Million INR | -3.18% |
| 2016 | 575.39 Million INR | -28.08% |
| 2015 | 800.09 Million INR | -6.11% |
| 2014 | 852.13 Million INR | -0.06% |
| 2013 | 852.68 Million INR | 6.44% |
| 2012 | 801.12 Million INR | 42.86% |
| 2011 | 560.75 Million INR | 6.73% |
| 2010 | 525.39 Million INR | 16.58% |
| 2009 | 450.68 Million INR | 0.32% |
| 2008 | 449.26 Million INR | 59.51% |
| 2007 | 281.65 Million INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 179.32 Million INR | 1.19% |
| 2023 Q1 | 157.02 Million INR | 31.15% |
| 2023 Q2 | 243.15 Million INR | 54.85% |
| 2023 Q3 | 217.46 Million INR | -10.56% |
| 2023 Q4 | 177.21 Million INR | -18.51% |
| 2023 FY | 794.86 Million INR | 27.22% |
| 2022 Q1 | 171.23 Million INR | -37.68% |
| 2022 Q2 | 180.8 Million INR | 5.59% |
| 2022 Q3 | 153.03 Million INR | -15.36% |
| 2022 Q4 | 119.72 Million INR | -21.76% |
| 2022 FY | 624.8 Million INR | -30.65% |
| 2021 FY | 900.93 Million INR | 16.94% |
| 2021 Q2 | 214.62 Million INR | -1.07% |
| 2021 Q4 | 274.78 Million INR | 44.56% |
| 2021 Q3 | 190.08 Million INR | -11.43% |
| 2021 Q1 | 216.95 Million INR | 50.28% |
| 2020 FY | 770.4 Million INR | 11.44% |
| 2020 Q1 | 124.65 Million INR | -31.77% |
| 2020 Q2 | 292.44 Million INR | 134.6% |
| 2020 Q3 | 209.22 Million INR | -28.46% |
| 2020 Q4 | 144.36 Million INR | -31.0% |
| 2019 Q4 | 182.69 Million INR | -8.17% |
| 2019 Q2 | 141.47 Million INR | -15.9% |
| 2019 Q3 | 198.94 Million INR | 40.63% |
| 2019 FY | 691.32 Million INR | 25.63% |
| 2019 Q1 | 168.21 Million INR | 10.99% |
| 2018 Q3 | 150.97 Million INR | 7.05% |
| 2018 FY | 550.3 Million INR | -1.22% |
| 2018 Q2 | 141.03 Million INR | 32.14% |
| 2018 Q1 | 106.73 Million INR | -26.47% |
| 2018 Q4 | 151.55 Million INR | 0.38% |
| 2017 Q3 | 208.75 Million INR | 58.56% |
| 2017 Q1 | 71.55 Million INR | -50.04% |
| 2017 FY | 557.11 Million INR | -3.18% |
| 2017 Q4 | 145.16 Million INR | -30.46% |
| 2017 Q2 | 131.65 Million INR | 83.99% |
| 2016 FY | 575.39 Million INR | -28.08% |
| 2016 Q4 | 143.22 Million INR | 1.73% |
| 2016 Q3 | 140.78 Million INR | 2.62% |
| 2016 Q1 | 154.08 Million INR | -25.54% |
| 2016 Q2 | 137.19 Million INR | -10.96% |
| 2015 FY | 800.09 Million INR | -6.11% |
| 2015 Q3 | 208.67 Million INR | 1.93% |
| 2015 Q2 | 204.71 Million INR | 13.88% |
| 2015 Q1 | 179.77 Million INR | -23.55% |
| 2015 Q4 | 206.93 Million INR | -0.83% |
| 2014 Q1 | 164.61 Million INR | -12.53% |
| 2014 Q4 | 235.14 Million INR | -0.71% |
| 2014 FY | 852.13 Million INR | -0.06% |
| 2014 Q2 | 215.56 Million INR | 30.95% |
| 2014 Q3 | 236.81 Million INR | 9.86% |
| 2013 Q2 | 251.96 Million INR | 13.97% |
| 2013 Q4 | 188.18 Million INR | -1.67% |
| 2013 FY | 852.68 Million INR | 6.44% |
| 2013 Q3 | 191.38 Million INR | -24.04% |
| 2013 Q1 | 221.07 Million INR | -0.88% |
| 2012 Q3 | 232.4 Million INR | 12.71% |
| 2012 Q2 | 206.2 Million INR | 47.81% |
| 2012 Q4 | 223.02 Million INR | -4.03% |
| 2012 Q1 | 139.5 Million INR | -3.63% |
| 2012 FY | 801.12 Million INR | 42.86% |
| 2011 Q2 | 143.5 Million INR | 0.0% |
| 2011 Q4 | 144.75 Million INR | -6.85% |
| 2011 FY | 560.75 Million INR | 6.73% |
| 2011 Q3 | 155.4 Million INR | 8.29% |
| 2010 FY | 525.39 Million INR | 16.58% |
| 2009 FY | 450.68 Million INR | 0.32% |
| 2008 FY | 449.26 Million INR | 59.51% |
| 2007 FY | 281.65 Million INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.836% |
| NATCO Pharma Limited | 40.02 Billion INR | 98.014% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 92.44% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | 69.339% |
| Achyut Healthcare Limited | 61.36 Million INR | -1195.216% |
| Ajanta Pharma Limited | 42.08 Billion INR | 98.111% |
| Alkem Laboratories Limited | 126.67 Billion INR | 99.373% |
| Alpa Laboratories Limited | 1.08 Billion INR | 26.902% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 98.7% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 93.865% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 99.723% |
| Bajaj HealthCare Limited | 4.73 Billion INR | 83.21% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 89.68% |
| Divi's Laboratories Limited | 78.45 Billion INR | 98.987% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 99.715% |
| Eris Lifesciences Limited | 20.09 Billion INR | 96.044% |
| FDC Limited | 19.42 Billion INR | 95.909% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 99.327% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 96.519% |
| Granules India Limited | 45.06 Billion INR | 98.236% |
| Gufic Biosciences Limited | 8.06 Billion INR | 90.146% |
| Hester Biosciences Limited | 3.04 Billion INR | 73.9% |
| Indoco Remedies Limited | 17.89 Billion INR | 95.558% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 93.795% |
| Ipca Laboratories Limited | 76.22 Billion INR | 98.957% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | 61.914% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -57.643% |
| Lasa Supergenerics Limited | 1.04 Billion INR | 23.816% |
| Laurus Labs Limited | 50.01 Billion INR | 98.411% |
| Lupin Limited | 200.1 Billion INR | 99.603% |
| Mankind Pharma Limited | 103.34 Billion INR | 99.231% |
| Medicamen Biotech Limited | 1.79 Billion INR | 55.67% |
| Medico Remedies Limited | 1.44 Billion INR | 45.152% |
| Megasoft Limited | 373.95 Million INR | -112.556% |
| Piramal Pharma Limited | 81.71 Billion INR | 99.027% |
| RPG Life Sciences Limited | 5.82 Billion INR | 86.344% |
| Sigachi Industries Limited | 3.98 Billion INR | 80.076% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -5.216% |
| Unichem Laboratories Limited | 16.57 Billion INR | 95.204% |
| Wanbury Limited | 5.75 Billion INR | 86.192% |
| Windlas Biotech Limited | 6.3 Billion INR | 87.402% |
| ZIM Laboratories Limited | 3.67 Billion INR | 78.367% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 99.582% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 93.096% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | 81.13% |
| Bal Pharma Limited | 3.39 Billion INR | 76.568% |
| Strides Pharma Science Limited | 40.51 Billion INR | 98.038% |
| Venus Remedies Limited | 5.91 Billion INR | 86.561% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 95.622% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 95.28% |
| Shilpa Medicare Limited | 11.51 Billion INR | 93.098% |
| Aarti Drugs Limited | 25.28 Billion INR | 96.856% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 96.249% |
| Suven Life Sciences Limited | 116.92 Million INR | -579.781% |
| Ind-Swift Limited | 5.02 Billion INR | 84.181% |
| Valiant Laboratories Limited | 1.82 Billion INR | 56.34% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 97.719% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 93.581% |
| Themis Medicare Limited | 3.81 Billion INR | 79.179% |
| Hikal Limited | 17.84 Billion INR | 95.546% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 99.251% |
| Sequent Scientific Limited | 13.69 Billion INR | 94.197% |
| Novartis India Limited | 3.35 Billion INR | 76.278% |
| Wockhardt Limited | 27.89 Billion INR | 97.15% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 98.814% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -98.54% |
| Neuland Laboratories Limited | 15.58 Billion INR | 94.9% |
| Morepen Laboratories Limited | 17.01 Billion INR | 95.33% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | 48.51% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | 78.435% |